Related Experiment Video
Updated: Apr 26, 2026

Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development
Published on: May 17, 2024
Serum nesfatin-1 levels in overt and subclinical hyperthyroidism
1Department of Endocrinology and Metabolic Diseases Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey - askn79@yahoo.com.
Aim:
Nesfatin-1 was recently discovered anorexigenic peptide in the brain which is derived from nucleobindin-2. Central and peripheral administration of nesfatin-1, inhibits food intake, dose-dependently. Hyperthyroid patients have increased appetite and food intake with a craving for carbohydrate-rich food, at the beginning of disease, but the physiological mechanisms underlying this behavior is not known exactly. In this study, we investigated whether nesfatin-1 is involved in the regulation of appetite and body weight in hyperthyroidism, or not.
Methods:
A total of 70 patients with subclinical (35) and overt hyperthyroidism (35) compared with 35 control patients. Serum nesfatin-1 level was measured from all samples by commercial ELISA kit.
Results:
Serum nesfatin-1 levels were similar between three groups (P=0.293). After adjusting for age and body mass index, nesfatin-1 levels in control group was not different from subclinical and overt hyperthyroid group, respectively (P=0.567 and P=0.519).
Conclusion:
These data showed that serum nesfatin-1 levels do not significant change in overt and subclinical hyperthyroidism.
Related Concept Videos
Hyperthyroidism I: Introduction
Hyperthyroidism II: Pathophysiology
Nephrotic Syndrome I : Introduction
Hypothyroidism II: Pathophysiology
Nephrotic Syndrome II : Assessment and Medical Management
Serum Studies: Renal Function Tests
